Pulmatrix Announces FDA Acceptance Of IND Application For PUR3100 To Treat Acute Migraine
Portfolio Pulse from Benzinga Newsdesk
Pulmatrix has received FDA approval for its Investigational New Drug (IND) application for PUR3100, a treatment for acute migraine. The company has also received a 'study may proceed' letter for a Phase 2 study of the drug.
September 19, 2023 | 1:06 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Pulmatrix's FDA approval for its IND application for PUR3100 could potentially boost the company's stock in the short term.
FDA approval for an IND application is a significant milestone for any pharmaceutical company. This approval allows Pulmatrix to proceed with a Phase 2 study of PUR3100, which could potentially lead to a new revenue stream if the drug is eventually approved for market. This news is likely to be viewed positively by investors, potentially leading to an increase in Pulmatrix's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100